Clinical trials: B-cell Malignancies
B Cell Precursor Acute Lymphoblastic Leukemia
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to…
- Trial name
- NCT04521231
- Testing
- Blinatumomab
- Where
- 109 sites in United States, Argentina and 18 more
- Volunteers
- 181 people
- Sponsor
- Amgen
Lymphoma, B Cell Lymphoma
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
The is a prospective, open-label, dose-climbing multicenter clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
- Conditions
- Lymphoma, B Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma
- Trial name
- CAR-T，MTD (NCT07048353)
- Testing
- chimeric antigen receptor gene modified T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Diffuse Large B-Cell Lymphoma
A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
Approximately 500 subjects will be enrolled in this study. Subjects who meet the inclusion criteria will be randomized (1:1) into two groups.
- Trial name
- NCT03670901
- Testing
- JHL1101, MabThera
- Where
- China
- Volunteers
- 8 people
- Sponsor
- JHL Biotech, Inc.
Multiple Myeloma
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants…
- Trial name
- DREAMM 8 (NCT06956170)
- Testing
- Belantamab mafodotin, Pomalidomide, Dexamethasone
- Where
- 13 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
B-cell Mediated Autoimmune Disorders
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
- Trial name
- NCT06680037
- Testing
- Azercabtagene zapreleucel (azer-cel)
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- TG Therapeutics, Inc.
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia.
- Trial name
- NCT04245722
- Testing
- FT596, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 98 people
- Sponsor
- Fate Therapeutics
Non-Hodgkin's Lymphoma
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP
The purpose of this study is to determine the safety and effectiveness of using Iodine-131 Anti-B1 Antibody for the treatment of patients with large B-cell non-Hodgkin's lymphoma (NHL) who have achieved a response following 6-8…
- Trial name
- NCT00022932
- Testing
- Iodine-131 Anti-B1 Antibody
- Where
- 3 sites in United States
- Sponsor
- Corixa Corporation
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a multicenter, randomized, controlled, open-label Phase III clinical trial, aimed at evaluating the efficacy and safety of BEBT-908 combined with rituximab (R) compared to investigator-selected standard chemotherapy…
- Trial name
- NCT06792253
- Testing
- Ifupinostat Hydrochloride for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection
- Where
- China
- Volunteers
- 416 people
- Sponsor
- BeBetter Med Inc
Chronic Lymphocytic Leukemia
Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
Open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT01557777
- Testing
- Navitoclax
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 17 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Leukemia, Acute Myeloid, Myelodysplastic Syndromes
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment.
- Conditions
- Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell
- Trial name
- NCT05362773
- Testing
- MGD024
- Where
- 7 sites in United States
- Volunteers
- 130 people
- Sponsor
- MacroGenics
Diffuse Large B-Cell Lymphoma
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
- Trial name
- GlofitReal (NCT07200375)
- Testing
- Glofitamab
- Where
- 22 sites in China, Hong Kong
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
This study will evaluate the efficacy and safety of intense combination treatment including MabThera/Rituxan (rituximab), followed by MabThera/Rituxan maintenance therapy in patients with B-cell CLL who are naive to chemotherapy.
- Trial name
- NCT02013817
- Testing
- rituximab [MabThera/Rituxan], fludarabine, cyclophosphamide
- Where
- 8 sites in Austria
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Burkitt Lymphoma, Lymphoma, Follicular
A Safety Study of SGN-CD19A for B-Cell Lymphoma
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
- Conditions
- Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
- Trial name
- NCT01786135
- Testing
- SGN-CD19A
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Seagen Inc.
Lymphoma, B-Cell
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).
- Trial name
- NCT00073749
- Testing
- Inotuzumab ozogamicin [CMC-544]
- Where
- 22 sites in United States, Belgium and 5 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Tumors With Aberrations in ALK or ROS1
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
The purpose of this signal seeking study was to determine whether treatment with ceritinib demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
- Trial name
- SIGNATURE (NCT02186821)
- Testing
- Ceritinib
- Where
- 21 sites in United States
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphoma
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma
RATIONALE: BL22 immunotoxin can find tumor cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating patients with refractory B-cell…
- Trial name
- NCT00126646
- Testing
- BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- MedImmune LLC
Lymphoma, B-Cell
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B), rituximab plus gemcitabine and platinum-based…
- Trial name
- NCT04882163
- Testing
- CC-220, Polatuzumab vedotin, Rituximab
- Where
- 27 sites in United States, Austria and 6 more
- Sponsor
- Celgene
Acute Leukemia, Acute Lymphoblastic Leukemia
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain…
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
- Trial name
- NCT05589896
- Testing
- Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC)
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ossium Health, Inc.
Acute Lymphoblastic Leukemia
A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
- Trial name
- NCT07066397
- Testing
- ARM011, Fludarabine, Cyclophosphamide
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- TriArm Therapeutics (Taiwan) Limited
B-Cell Chronic Lymphocytic Leukemia
Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Study of Bafetinib as Treatment for Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL).
- Trial name
- NCT01144260
- Testing
- bafetinib
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- CytRx
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.